HK1208231A1 - Treatment for rheumatoid arthritis - Google Patents

Treatment for rheumatoid arthritis

Info

Publication number
HK1208231A1
HK1208231A1 HK15108769.5A HK15108769A HK1208231A1 HK 1208231 A1 HK1208231 A1 HK 1208231A1 HK 15108769 A HK15108769 A HK 15108769A HK 1208231 A1 HK1208231 A1 HK 1208231A1
Authority
HK
Hong Kong
Prior art keywords
treatment
rheumatoid arthritis
rheumatoid
arthritis
Prior art date
Application number
HK15108769.5A
Other languages
English (en)
Chinese (zh)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HK1208231A1 publication Critical patent/HK1208231A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15108769.5A 2012-09-20 2015-09-09 Treatment for rheumatoid arthritis HK1208231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
HK1208231A1 true HK1208231A1 (en) 2016-02-26

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108769.5A HK1208231A1 (en) 2012-09-20 2015-09-09 Treatment for rheumatoid arthritis

Country Status (23)

Country Link
US (3) US20150246969A1 (xx)
EP (3) EP3345923A1 (xx)
JP (3) JP2015533806A (xx)
KR (4) KR20220028177A (xx)
CN (2) CN109999195A (xx)
AU (2) AU2013320261A1 (xx)
BR (1) BR112015006189B1 (xx)
CA (1) CA2884124A1 (xx)
CL (2) CL2015000696A1 (xx)
CR (1) CR20150153A (xx)
DO (1) DOP2015000070A (xx)
EA (1) EA031489B1 (xx)
HK (1) HK1208231A1 (xx)
IL (1) IL237554B (xx)
IN (1) IN2015KN00657A (xx)
MA (1) MA37946B1 (xx)
MX (2) MX2015003644A (xx)
MY (1) MY175388A (xx)
PE (1) PE20151079A1 (xx)
PH (1) PH12015500591A1 (xx)
SG (2) SG10201803778PA (xx)
UA (1) UA117228C2 (xx)
WO (1) WO2014044768A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533806A (ja) * 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療
JP6339578B2 (ja) * 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CN106659785B (zh) * 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
EA038551B1 (ru) 2015-12-17 2021-09-14 Дзе Джонс Хопкинс Юниверсити Способ лечения или профилактики системного склероза
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
CN109219616B (zh) 2016-09-19 2022-10-21 天境生物科技(杭州)有限公司 Gm-csf抗体及其用途
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN1142940C (zh) 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
SG176503A1 (en) * 2006-11-21 2011-12-29 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
MX2009010389A (es) * 2007-03-30 2010-01-20 Medimmune Llc Formulacion de anticuerpos.
TW200902725A (en) * 2007-04-02 2009-01-16 Genentech Inc Biological markers predictive of rheumatoid arthritis response to B-cell antagonists
AU2008235044B2 (en) 2007-04-05 2011-08-25 Sandoz Ag Stable aqueous G-CSF formulations
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PT2215119E (pt) * 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
ES2685895T3 (es) * 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
SI2376121T1 (sl) 2008-12-22 2016-07-29 The University Of Melbourne Zdravljenje osteoartritisa
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
PT2341061E (pt) 2009-12-31 2013-11-05 Arven Ilac Sanayi Ve Ticaret As Um processo novo para a preparação de g-csf (fator de estimulação de colónias de granulócitos)
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
KR20140061379A (ko) 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
JP2015533806A (ja) * 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療

Also Published As

Publication number Publication date
CL2018000933A1 (es) 2018-07-20
CN104995210A (zh) 2015-10-21
JP2022169709A (ja) 2022-11-09
CR20150153A (es) 2015-09-14
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
MA37946B1 (fr) 2018-09-28
IL237554A0 (en) 2015-04-30
EP3916013A1 (en) 2021-12-01
PH12015500591B1 (en) 2015-05-11
UA117228C2 (uk) 2018-07-10
AU2016250388A1 (en) 2016-11-17
EA201590359A1 (ru) 2015-08-31
SG10201803778PA (en) 2018-06-28
MX2015003644A (es) 2015-09-25
JP2018138551A (ja) 2018-09-06
CN109999195A (zh) 2019-07-12
US20150246969A1 (en) 2015-09-03
BR112015006189A2 (pt) 2019-11-26
MA37946A1 (fr) 2018-01-31
DOP2015000070A (es) 2015-08-16
KR20220028177A (ko) 2022-03-08
KR20240091288A (ko) 2024-06-21
EA031489B1 (ru) 2019-01-31
CA2884124A1 (en) 2014-03-27
AU2016250388B2 (en) 2018-07-19
BR112015006189B1 (pt) 2022-04-05
IL237554B (en) 2019-12-31
JP2015533806A (ja) 2015-11-26
PE20151079A1 (es) 2015-08-07
IN2015KN00657A (xx) 2015-07-17
MX2021006111A (es) 2021-07-07
EP2897977A1 (en) 2015-07-29
US20210130451A1 (en) 2021-05-06
EP3345923A1 (en) 2018-07-11
PH12015500591A1 (en) 2015-05-11
US10913792B2 (en) 2021-02-09
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
CL2015000696A1 (es) 2015-10-23
AU2013320261A1 (en) 2015-04-09
KR20150056846A (ko) 2015-05-27
US20180230208A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
HK1208231A1 (en) Treatment for rheumatoid arthritis
HK1219414A1 (zh) 治療關節炎的方法
EP2787497A4 (en) DEFAULT ASSESSMENT APPARATUS
GB201014633D0 (en) Rheumatoid arthritis treatment
EP2875825A4 (en) COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS
EP2871630A4 (en) DEVICE FOR MONITORING MONITORING
HK1200855A1 (en) Treatment for rheumatoid arthritis
EP2833380A4 (en) REACTOR APPARATUS
GB201218666D0 (en) Apparatus
HUE045341T2 (hu) Úttisztító berendezés
GB2504133B (en) Improved apparatus
GB2502268B (en) Improved apparatus
EP2852559A4 (en) METHOD OF TREATING MUD
HK1249427A1 (zh) 關節炎治療
GB201220673D0 (en) Apparatus
GB201300914D0 (en) Apparatus
GB201218575D0 (en) Nephroureterectomy apparatus
HK1209999A1 (en) Apparatus
GB201215796D0 (en) Apparatus
EP2929742A4 (en) TRACKING DEVICE
ZA201501559B (en) Treatment for rheumatoid arthritis
GB2513286B (en) Apparatus
GB201219911D0 (en) Arthritis pain reducer
HUP1200221A2 (en) Sludge treatment
GB201218041D0 (en) Methods compounds for preventing arthritis